
ARC : les 5 conditions essentielles pour réaliser un monitoring clinique de qualité
Monitoring clinique : les 5 piliers dont l’ARC a besoin pour un monitoring de qualité, des besoins fondamentaux à l’accomplissement.
Les consentements éclairés ? Est-il possible d’utiliser un support électronique afin d’informer et de recueillir le consentement éclairé d’un patient ? Quels sont les bénéfices et les limites de cette méthode ?

Article rédigé par la Société Pharmaspecific, spécialiste en recherche clinique
I wanted to thank Helen Marquet who helped me in writing this article.
The electronic way is increasingly used both in everyday life and in clinical research. Indeed, more and more exchanges are done electronically with the project team, investigators or even the Competent Authorities (Ethics Committee), ANSM. The study data are collected on electronic CRF and some hospitals have electronic medical records. So why not the informed consents? Is it possible to use electronic support to inform and obtain the informed consent of a patient? What are the advantages and limits of this method?
Yes, the informed consent of a patient is possible in the United States. The Food and Drug Administration (FDA) recently issued draft recommendations on the matter.
According to these recommendations, « electronic consent is the use of electronic systems and processes that could be in the form of multiple supports: text, graphics, audio, video, podcasts and interactive websites, biological recognition devices and card readers to transmit information concerning the study and to obtain informed consent.”
Obviously, the requirements for the content of the information delivered to the patient remain the same, in accordance with Good Clinical Practices: the information should be easily understandable for the patient, scientific terms and abbreviations must be explained at the first use.
However, the use of electronic and interactive systems gives leads to new requirements:
The investigator has new methods to check that the patient have well understood the study, its potential risks and expected benefits: it is possible to add quizzes at the end of each section of the interactive electronic system.
The use of electronic support will then be allowed to transmit information to the patient, as long as this is understandable and appropriate, but also to collect the electronic signature of informed consent, if it complies with FDA regulation (Code of Federal Regulations title 21).
Under this Regulation, an electronic signature can be used when the said signature is reliable and equivalent to a handwritten paper signature. For this, the FDA recommends the use of systems such as encrypted electronic signatures, electronic signature pad, voice or fingerprint recognition signature (http://www.oscarservice.com/wp-content/uploads/2014/01/ePad-ink-w-hand_small .png).
This type of system will collect the patient’s consent on site, but also remotely, in his absence. The system must therefore be able to clearly identify the patient to certify electronic signature in order to ensure that the person who signs is the right patient who will participate in clinical research.The FDA therefore provides a framework for these electronic informed consents, but it is only a draft recommendation and not a regulation. However, since the recommendations publication, some CROs have implemented an electronic informed consent system in accordance with these recommendations.
According to the European Directive 2001/20 / EC, informed consent is a decision, which must be written, dated and signed, to take part in a clinical trial, taken freely after being duly informed of the nature, scope, consequences and risks and have received appropriate documentation.
Up to now, no action appears to have been made regarding electronic informed consent.
Particularly, some emerging countries are having a larger percentage of illiterate patients. According to GCPs, such patient requires the presence of an independent person from the investigator and promoter in order to read the information note to the patient.
To overcome this difficulty, India has authorized the collection of informed consent by video. The whole study explanation process by the investigator, questions from the patient, and the confirmation that the patient has understood are filmed by a member of the investigator’s team (listed on the tasks delegation form)
While solving main issues, this process still raises questions about patient confidentiality:
Electronic informed consent is a real improvement of its time. However, in this case, more than in the case of a paper form, every precaution must be taken to check the patient identity and above all, guarantee his confidentiality. Electronic informed consents have non-negligible advantages:
This system can enable promoter immediate notification in case of a new patient inclusion on site.
In case of amendment to the protocol, patients can be notified promptly of changes in the study and can sign the informed consent from their home.
However, as shown in the case of India, precautions must be taken in the some consent:
I hope this article provided you with relevant information on electronic consents. You can give your opinion on electronic informed consent in the comments.
Sophie Hammer
You can visit the Facebook page of « blog de la recherche clinique » and the « Pharmaspecific » and click on « I like » to support us.
See « Pharmaspecific Linkedin » and « Vanessa Montanari Linkedin » on LinkedIn for more relevant news on clinical researches.
See us as well on Pharmaspecific Viadeo and Vanessa Viadeo.
You can also subscribe on the blog’s newsletter we will keep you posted once a new article is published.{:}